Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Ascites × catumaxomab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 5 Carcinoma, Ovarian Epithelial 4 Peritoneal Neoplasms 3 Fallopian Tube Neoplasms 3 Stomach Neoplasms 2 Carcinoma 2 Neoplasms, Glandular and Epithelial 1 Neoplasms 1 Ascites 1 Adenocarcinoma 1

Interventions

sintilimab 1 danvatirsen 1 catumaxomab 1 Octreotide 1 Blood Specimen Collection 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00326885 2018-10-17

Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites

Neovii Biotech

Phase 2 Completed

32 enrolled 12 charts

Carcinoma, Ovarian Epithelial, Ascites, Carcinoma, Fallopian Tube Neoplasms, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡